CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 38 enrolled
Drug / intervention
Diet low in Advanced Glycation End-Products (AGE)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05104242
NCT05104242N/ACompleted
CompareCT.gov

A Feasibility Study Exploring the Impact of a Low Advanced Glycation End-product (AGE) Diet on Skin Autofluorescence (SAF) Levels in Kidney Transplant Recipients

University Hospitals of Derby and Burton NHS Foundation Trust·interventional·Posted Nov 2, 2021·Updated Dec 6, 2024

In Brief

A clinical study evaluating Diet low in Advanced Glycation End-Products (AGE) for Renal Transplant. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The purpose of the present study is to test the feasibility of conducting a larger randomised controlled trial (RCT) which will investigate whether a diet low in toxins called advanced glycation end-products (AGEs) decreases skin autofluorescence (SAF; AGE accumulation in the skin) levels and improves heart and circulatory (i.e. cardiovascular) health in persons with a kidney transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant
CountriesUnited Kingdom
CollaboratorsBritish Renal Society, Kidney Care UK

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 2, 2021
Enrollment StartFeb 4, 2022
Primary CompletionDec 8, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.7 years ago

Interventions

Diet low in Advanced Glycation End-Products (AGE)other

The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences